- 2023.06.03
As a global innovative biotech company, we are passionate about creating transformational therapies through innovation to address unmet medical needs in oncology for patients worldwide.
Lemzoparlimab CD47
Uliledlimab CD73
Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA, Probody
AI Design, Alphabody
Press Releases
2023.05.26
The Company reports encouraging clinical results of uliledlimab at the ASCO Annual Meeting.
2023.04.26
The Company will present a poster featuring the latest clinical data of uliledlimab in combination with PD-1 therapy in NSCLC at ASCO 2023.
2023.04.25
Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute.
Events